• Biodesix Closes Series D Financing

    July 14, 2011 Biodesix Inc., a fully integrated molecular diagnostic company developing products that improve clinical decision making , has closed on a $20 million Series D financing. The new capital will support ongoing commercialization activities for the Company’s first product VeriStrat®, a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC).  The financing ... Read more
  • Biodesix Supports Unique Lung Cancer Research Initiative – CASTLE study enrolls initial subjects

    May 6, 2011 Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute (ALCMI, pronounced as “Alchemy”). The CASTLE (Collaborative Advanced Stage Tissue Lung Cancer) study is recruiting a minimum of 250 subjects over two years among academic and community medical centers in the United States. The study collects ... Read more
  • Biodesix Issued Four Additional U.S. Patents for Blood-based Oncology Tests

    April 12, 2011 Biodesix, Inc., a fully integrated molecular diagnostics company advancing products for personalized medicine, today announced that the U.S. Patent & Trademark Office (PTO) has issued four patents which collectively provide broad intellectual property protection for the Company’s products and technology. The patents provide additional coverage in multiple tumor types for the Company’s first product, VeriStrat®, which is used by ... Read more
  • Biodesix Receives Certification from NY State

    March 1, 2011 Biodesix, Inc., a fully integrated molecular diagnostics company advancing the development of products for personalized medicine, today announced that they have received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center. With this certification, VeriStrat®, a serum proteomic test to help physicians guide treatment for patients with non-small cell ... Read more
  • Biodesix to Present at 2011 Biotech Showcase

    January 7, 2011 Biodesix, Inc. announces that Paul Beresford, Ph.D., Vice President, Business Development and Strategic Marketing will present at the 2011 Biotech Showcase conference taking place January 10-12th at the Parc 55 Wyndham in San Francisco, California. Biodesix’ presentation will occur on Monday, January 10th, at 2:15 p.m. Pacific time.  Dr. Beresford will provide a corporate overview ... Read more
  • VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy

    November 19, 2010 Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer (NSCLC) were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical ... Read more
  • Biodesix Completes Series C Financing and Receives Grant

    November 5, 2010 Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors. The Series C round, which included 5 new investors, will support ongoing commercialization activities for the company’s first product VeriStrat®, a serum proteomic test that helps physicians guide treatment for patients with non-small cell lung cancer ... Read more
  • Biodesix Selected as a Colorado Company to Watch

    June 23, 2010 Biodesix Inc. announced today that they are one of the winners of the 2010 Colorado Companies to Watch award.  Colorado Companies to Watch is a dynamic business recognition program honoring second-stage companies headquartered in the state of Colorado that are developing valuable products and services, creating quality jobs, enriching communities, and building new industries throughout ... Read more
  • Biodesix Announces Issuance of Key Patent for Serum Test that Identifies Lung Cancer Patients Likely to Benefit from Targeted Therapy

    June 21, 2010 Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905.  The patent provides coverage for the Company’s first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer.  ... Read more
  • New Data from Phase III Lung Cancer Trial Show VeriStrat® Identifies Patients Likely to Respond to Erlotinib

    May 6, 2010 Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed oral therapy for advanced ... Read more